Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

454.50
Delayed Data
As of Mar 27
 +6.13 / +1.37%
Today’s Change
269.50
Today|||52-Week Range
495.50
+10.79%
Year-to-Date
3 Little-Known Biotechs Working On Potential Blockbusters
Mar 28 / MotleyFool.com
Esperion Soars on Positive Phase IIb Data on ETC-1002 - Analyst Blog
Mar 18 / Zacks.com
Biotechs Need to Rest
Mar 27 / TheStreet.com
Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog
Mar 18 / Zacks.com
Regeneron's Eylea Gets FDA Approval for Label Expansion - Analyst Blog
Mar 26 / Zacks.com
Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Anal...
Mar 18 / Zacks.com
Stock Market News for March 26, 2015 - Market News
Mar 26 / Zacks.com
Stock Market News for March 18, 2015 - Market News
Mar 18 / Zacks.com
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
Mar 25 / TheStreet.com
Pharma Stock Outlook: Let's Make a Deal - Industry Outlook
Mar 17 / Zacks.com
Dow tumbles 292 points as economy shows cracks
Mar 25 / CNNMoney.com
Pharma Stock Outlook: Let's Make a Deal - Zacks Analyst Interviews
Mar 17 / Zacks.com
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Updat...
Mar 25 / Zacks.com
Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog
Mar 16 / Zacks.com
High Alert for Signs of Biotech Collapse Makes for Nervous Investors
Mar 24 / TheStreet.com
Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog
Mar 16 / Zacks.com
2015 Biotech ETF Surge Reflects Healthy Sector
Mar 23 / Investing Channel
Vertex climbs on drug approval hopes
Mar 05 / FT.com
The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics...
Mar 19 / Zacks.com
6 stocks that left the bull market in the dust
Mar 05 / CNNMoney.com

To view my watchlist

Not a member yet?

Sign up now for a free account